Assertion Supported
Juneja: Weak regulation leads to heavy metals like lead in Ayurvedic drugs
“The purity is an issue, actually. And a lot of time when regulatory is not very, very strong there are complaints of, I'll say, adding certain other things in that. For example, in this in some of the drugs, lead has been found.”
Opinion
Juneja: Halting Chinese intermediate supplies would spark an Indian antibiotic crisis
“A lot of antibiotics are there. In the absence of Chinese supply, we can come into a crisis.”
Disclosure
Juneja: Mankind Pharma intentionally caps EBITDA at 26% to fuel growth
“See, I mean, it depends upon, I mean, if you just look at mankind, our EBITDA is always in between 25, 26%.
Intentionally.
Because we just want to grow faster.
We spend more.
We can increase it.”
Insight
Juneja: Low drug prices make government Jan Aushadhi pharmacy franchises commercially unviable
“Because if you sell something at a very cheap price, to run that Jan Ojdi, is a problem. You can look, if your daily sale is say, for example, 2000 rupees, what will you earn out of that? You need to have at least 50,001 lakh rupees sales daily. Then you earn …”
Insight
Juneja: Ayurvedic doctors lose patients if they prescribe only slow-acting Ayurvedic remedies
“If a patient is coming to him, and if he prescribes only Ayurveda product, the patient will not come back to him. Because patient needs what? Instant relief. Faster relief.”
Disclosure
Juneja: Mankind will use semaglutide as a frontend to cross-sell lifestyle supplements
“So what our philosophy is, along with this, our focus would be on supplements. I mean, this would be front end, but actually, we will be selling the complete lifestyle. Protein, supplements, vitamins, other requirements. The complete, I mean, chain, the ecosys…”
Insight
Juneja: Pharma sales reps for unbranded companies must become personal brands
“So when you work in that kind of a company, ah, if you will not become a brand yourself, ah, company will not run.”
Assertion Not checkable as stated
Juneja: 1984 Meerut pharma venture started with ₹69,000 outperformed Glaxo locally
“One time that company start, which was started with 69,000 rupees in 84, became Merit's number one company. We had written Blaxos, Cibla, any company, everybody. Every company.”
Assertion Supported
Juneja: Indian pharmaceutical companies manufacture up to 50% of US medications
“That 40, 50% price that you buy over there are manufactured here. Indian companies.”
Assertion Partly supported
Juneja: Branded generics account for 95% of all drugs sold in India
“In India, first of all you're supposed to understand that, I mean 95% products are branded generic.”
Disclosure
Juneja: Mankind Pharma intentionally priced products 60% below leading competitor brands
“Keeping everything in mind, we intentionally kept our prices, 50%, 60%, 40%, more affordable than best of the companies.”
Insight
Juneja: Gen Z supplement buyers prioritize attractive branding and flavors over price
“Cost is not the most important thing in this Gen Z crowd. I mean, for example, this youth, where if somebody is concerned about his health, he wants a flavor, he wants a good looking, ah, tablet, capsules. I mean, see point is not, ah, bringing the same thing …”
Disclosure
Juneja: Mankind Pharma will not acquire Bold Care due to Manforce ownership
“Are you interested in buying Bold Care? No. We have our own man force. We've got many opportunities of buying them in different kind of brands, but man force is man force.”
Opinion
Juneja: Prevention and immunity are the biggest commercial opportunities in Ayurveda
“Biggest in Ayurveda would be prevention side or immunity side.”
Insight
Juneja: Heavy pharma R&D requires a global market presence to be viable
“If you're basically spending money on R&D, you're supposed to have global presence. Then only it will make some kind of a sense. Only from India, not possible.”
Disclosure
Juneja: Mankind Pharma’s hypertension drug Telmikind generates ₹1,000 crore in revenue
“One product, which is quite a big one, is tell me kind. It's for hypertension. 1000 crore rupees.”
Disclosure
Juneja: Mankind Pharma’s Manforce condom brand generates ₹600 crore in revenue
“Second brand would be Manforce. That's quite a known name. Condoms. Around together, 600 crore rupees.”
Assertion Supported
Juneja: India’s top 50 pharma companies command 80% domestic market share
“Top 50 companies have a share of more than approximately 80%.
75, 80%.”
Disclosure
Juneja: Mankind Pharma employs 17,000 pharmaceutical field sales representatives
“We have 17,000.”
Assertion Not publicly verifiable
Juneja: Only 20% of Indian doctors are affiliated with hospital chains
“So I feel today approximately 15, 20% doctors would be attached with hospitals.”
Assertion Partly supported
Juneja: Online sales of condoms in India are growing at 60% annually
“And if you just look at this right now, there is approximately, 50, 60% growth of condom sales online.”
Prediction Open · timeframe Jun 2029
Juneja: GLP-1 adoption will drive increased sales of protein and nutritional supplements
“What we basically imagine, going forward, the sales of protein products, different kind of proteins, supplements, protein supplements, vitamins, minerals, other enzymes, cocaine, all sort of things, they will further increase.”
Disclosure
Juneja: Mankind Pharma spends 2.75% of revenue on R&D, planning annual increases
“See, a company like us, we spend 2.75% on R&D. And what we've decided now, every year, we're supposed to increase it by 5.5%.”
Assertion Partly supported
Juneja: Up to 2% of all manufactured medicines expire before consumption
“Approximately, the 1.5 to two percent of medicines get expired.”
